Rifaximin Patent Expiration
Rifaximin is Used for treating travelers' diarrhea, reducing risk of hepatic encephalopathy episodes, and managing symptoms of irritable bowel syndrome with diarrhea. It was first introduced by Salix Pharmaceuticals Inc
Rifaximin Patents
Given below is the list of patents protecting Rifaximin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xifaxan | US10314828 | Methods of treating hepatic encephalopathy | Oct 02, 2029 | Salix Pharms |
| Xifaxan | US8642573 | Methods of treating hepatic encephalopathy | Oct 02, 2029 | Salix Pharms |
| Xifaxan | US8969398 | Methods of treating hepatic encephalopathy | Oct 02, 2029 | Salix Pharms |
| Xifaxan | US10314828 | Methods of treating hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US10335397 | Methods of treating hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US10709694 | Methods of treating hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US7928115 | Methods of treating travelers diarrhea and hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US8829017 | Methods of treating traveler's diarrhea and hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US8946252 | Methods of treating traveler's diarrhea and hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US9421195 | Methods of treating hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US9629828 | Methods of treating traveler's diarrhea and hepatic encephalopathy | Jul 24, 2029 | Salix Pharms |
| Xifaxan | US8309569 | Methods for treating diarrhea-associated irritable bowel syndrome | Jul 18, 2029 | Salix Pharms |
| Xifaxan | US10456384 | Methods for treating irritable bowel syndrome (IBS) | Feb 26, 2029 | Salix Pharms |
| Xifaxan | US10765667 | Methods for treating irritable bowel syndrome (IBS) | Feb 26, 2029 | Salix Pharms |
| Xifaxan | US11564912 | Methods for treating irritable bowel syndrome (IBS) | Feb 26, 2029 | Salix Pharms |
| Xifaxan | US11779571 | Methods for treating irritable bowel syndrome (IBS) | Feb 26, 2029 | Salix Pharms |
| Xifaxan | US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Sep 02, 2027 | Salix Pharms |
| Xifaxan | US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Sep 02, 2027 | Salix Pharms |
| Xifaxan | US10703763 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Feb 27, 2026 | Salix Pharms |
| Xifaxan | US8518949 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Feb 27, 2026 | Salix Pharms |
| Xifaxan | US8741904 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Feb 27, 2026 | Salix Pharms |
| Xifaxan | US9271968 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | Feb 27, 2026 | Salix Pharms |
| Xifaxan | US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun 01, 2025
(Expired) | Salix Pharms |
| Xifaxan | US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun 01, 2025
(Expired) | Salix Pharms |
| Xifaxan | US7915275 | Use of polymorphic forms of rifaximin for medical preparations |
Feb 23, 2025
(Expired) | Salix Pharms |
| Xifaxan | US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US7612199 | Polymorphic forms α, β, and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US7612199 | Polymorphic forms α, β, and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US7902206 | Polymorphic forms α, β and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US7902206 | Polymorphic forms α, β and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US8158644 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US8158781 | Polymorphic forms α, β and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US8158781 | Polymorphic forms α, β and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US8835452 | Polymorphic forms α, β and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US8853231 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun 19, 2024
(Expired) | Salix Pharms |
| Xifaxan | US6861053 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug 11, 2019
(Expired) | Salix Pharms |
| Xifaxan | US7452857 | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug 11, 2019
(Expired) | Salix Pharms |
| Xifaxan | US7605240 | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug 11, 2019
(Expired) | Salix Pharms |
| Xifaxan | US7718608 | Methods of treating a subject suffering from irritable bowel syndrome |
Aug 11, 2019
(Expired) | Salix Pharms |
| Xifaxan | US7935799 | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug 11, 2019
(Expired) | Salix Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rifaximin's patents.
Latest Legal Activities on Rifaximin's Patents
Given below is the list recent legal activities going on the following patents of Rifaximin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2024 | US8309569(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2024 | US10765667 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2024 | US9421195 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Dec, 2023 | US10703763 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10709694 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8193196(Litigated) |
| Email Notification Critical | 11 Oct, 2023 | US11779571 |
| Mail Patent eGrant Notification | 10 Oct, 2023 | US11779571 |
| Patent eGrant Notification | 10 Oct, 2023 | US11779571 |
| Recordation of Patent eGrant | 10 Oct, 2023 | US11779571 |
Rifaximin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List